INC Research Holdings, a, global phase I to IV CRO based in Raleigh, N.C., has announced the promotions of Alistair Macdonald and Michael Gibertini, Ph.D., to key roles within the C-suite.

Macdonald, who has worked as the company’s chief operating officer since January 2013, has been promoted to president and chief operating officer, while Gibertini, president and general manager, central nervous system (CNS) clinical development, has been appointed to the newly-created role of president, clinical development to lead the company’s therapeutic offerings globally.  

Prior to assuming the role of chief operating officer, Macdonald was president, clinical development services for INC Research. Macdonald has more than 20 years of experience in the pharmaceutical industry and has been with INC Research since 2002.  He is based in Camberley, U.K.

 Gibertini joined INC Research in 2005 and since that time has been president and general manager, CNS clinical development, providing global leadership for all clinical development programs conducted by the company in the CNS therapeutic area. Gibertini’s experience includes more than 30 years in the pharmaceutical, CRO, academic and private and hospital practice settings. In his new role, Gibertini will continue to report directly to CEO Jamie Macdonald.